Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors

22 Jan 2025

Abstract excerpt

Tumor lineage plasticity (LP) is an emerging hallmark of cancer progression. Through pharmacologically probing the function of epigenetic regulators in prostate cancer cells and organoids, we identified bromodomain protein BRD4 as a crucial player. Integrated ChIP-seq and RNA-seq analysis of tumors revealed, for the first time, that BRD4 directly activates hundreds of genes in the LP programs which include...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40370549
DOI: 10.1016/j.apsb.2025.01.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitorsPMID 40370549Read ↗

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

PROX1 is an early driver of lineage plasticity in prostate cancerSemantic proximity Read ↗

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity ProgramSemantic proximity Read ↗

Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancerSemantic proximity Read ↗

DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2Semantic proximity Read ↗

N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancerSemantic proximity Read ↗

Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1Semantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase functionSemantic proximity Read ↗

Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate CancerSemantic proximity Read ↗

Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer ProgressionSemantic proximity Read ↗

Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolutionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.